🇺🇸 FDA

Company profile · Sponsor

ALX

ALX ONCOLOGY HOLDINGS INC

ALXO · NYSE pharma SOUTH SAN FRANCISCO, CA, USA
Pipeline
13
Drugs
0
Patents
0

Quick answer

ALX (ALXO) is a pharma company. headquartered in SOUTH SAN FRANCISCO, CA, USA. listed on NYSE. NovaPharmaNews links 13 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker ALXO
Exchange NYSE
Company type pharma
Headquarters SOUTH SAN FRANCISCO, CA, USA
SEC CIK 0001810182

Pipeline (13)

Search pipeline →

  1. Evorpacept (ALX148)

    ALX

    Gastric Cancer

    phase 3 small molecule active

    1 trial

  2. AZACITIDINE

    ALX

    Patients with higher risk myelodysplastic syndrome (MDS) who have not yet been treated for their disease

    phase 2 small molecule active

    1 trial

  3. Evorpacept (ALX148)

    ALX

    Microsatellite Stable Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  4. Evorpacept (ALX148)

    ALX

    Breast Cancer, Metastatic

    phase 2 small molecule active

    1 trial

  5. Pembrolizumab

    ALX

    Ovarian Cancer

    phase 2 small molecule active

    1 trial

  6. Xeloda 150 mg film-coated tablets, Xeloda 500 mg film-coated tablets, Paclitaxel 6 mg/mL concentrate for solution for infusion, Herceptin 150 mg powder for concentrate for solution for infusion, GEMZAR 200 mg, poudre pour solution pour perfusion, HALAVEN 0.44 mg/ml solution for injection, Vinorelbine 10 mg/ml concentrate for solution for infusion, GEMZAR 1000 mg, poudre pour solution pour perfusion, evorpacept, HALAVEN 0.44 mg/ml solution for injection

    ALX

    Breast Cancer

    phase 2 small molecule active

    1 trial

  7. Zanidatamab

    ALX

    HER2-expressing Cancers

    phase 2 small molecule completed

    1 trial

  8. evorpacept

    ALX

    Head and Neck Cancer

    phase 2 small molecule active

    2 trials

  9. ALX2004

    ALX

    NSCLC (Advanced Non-small Cell Lung Cancer)

    phase 1 small molecule active

    1 trial

  10. Evorpacept

    ALX

    Bladder Cancer

    phase 1 small molecule completed

    1 trial

  11. Evorpacept (ALX148)

    ALX

    Metastatic Cancer

    phase 1 small molecule completed

    1 trial

  12. evorpacept

    ALX

    Higher Risk Myelodysplastic Syndromes

    phase 1 small molecule terminated

    1 trial

  13. evorpacept

    ALX

    Acute Myeloid Leukemia

    phase 1 small molecule terminated

    1 trial

Frequently asked questions

What is ALX?

ALX (ALXO) is a pharma company. headquartered in SOUTH SAN FRANCISCO, CA, USA. listed on NYSE. NovaPharmaNews links 13 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does ALX sponsor?

We track 13 ClinicalTrials.gov-linked programs for ALX, including Evorpacept (ALX148) and 12 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does ALX company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.